Sarepta Therapeutics (NASDAQ:SRPT)

CAPS Rating: 2 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar pchop123 (76.60) Submitted: 9/20/2012 10:39:17 AM : Outperform Start Price: $14.69 SRPT Score: +4.86

tremendous potential, buy on any dips or just buy

Report this Post Reply

Featured Broker Partners


Advertisement